Gene Therapy Market size was USD 7.35 Billion in 2022 and is expected to Reach USD 30.15 Billion by 2030 and grow at a CAGR of 19.3% over the forecast period of 2023-2030.
The gene therapy market refers to the segment of the pharmaceutical industry that focuses on the development and commercialization of gene therapies. Gene therapy is an innovative medical approach that aims to treat or cure genetic disorders by introducing, replacing, or modifying genes within a patient's cells. The fundamental concept behind gene therapy is to address the root cause of a genetic disorder rather than just managing its symptoms. This is achieved by delivering genetic material into the patient's cells to correct or compensate for the defective or missing genes. The gene therapy market has been rapidly growing in recent years due to significant advancements in biotechnology, genomics, and gene-editing technologies. Several gene therapies have received regulatory approval for specific genetic disorders, such as certain types of inherited blindness, spinal muscular atrophy, and rare immune deficiencies. The market potential for gene therapy is substantial, as it holds the promise of treating a wide range of genetic diseases that were previously considered incurable. However, it is essential to note that gene therapy is a complex and challenging field with various technical, regulatory, and ethical considerations.
Furthermore, increased government funding, ethical acceptance of gene therapy for cancer treatment, and an increase in cancer prevalence promote market expansion. Furthermore, growth in healthcare spending, the development of improved healthcare infrastructure, and the availability of reimbursements all contribute to the Gene Therapy Market Opportunity. However, the high cost of gene treatments is projected to limit market growth throughout the forecast period. The gene therapy market is divided into four sections: vector type, gene type, application, and location. It is divided into viral and non-viral vectors based on vector type. Retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, poxviruses, vaccinia viruses, and others comprise the viral vector section. The gene therapy market is highly competitive, with numerous biotechnology companies and pharmaceutical firms actively engaged in the research, development, and commercialization of gene therapies. The success of gene therapy in treating various genetic diseases has attracted significant investment and interest from both the scientific community and investors. Naked/plasmid vectors, gene guns, electroporation, lipofection, and other techniques are included in the non-viral vector sector. The market is divided into two types of therapy: ex vivo therapy and in vivo therapy. The market is divided into tumour suppressors, antigens, cytokine, receptors, suicide, growth factors, deficiency, and others based on gene type.
DRIVERS:
Significant progress in gene editing tools such as CRISPR-Cas9 has revolutionized the field of gene therapy.
A positive regulatory environment is a significant driving force in this industry.
Regulatory authorities in numerous nations, including the United States. Food & Drug Administration (FDA) and the European Medicines Agency (EMA), have been supportive of gene therapy development. Expedited pathways and special designations have been provided to facilitate the approval process for promising gene therapies.
RESTRAIN:
Gene therapy research and development involve complex scientific processes, rigorous clinical trials, and extensive regulatory requirements.
Manufacturing and Scale-up Challenges are the primary market restraints.
Scaling up the production of gene therapies to meet commercial demand can be difficult. Ensuring consistent and high-quality manufacturing processes is crucial, as any variability in the final product may impact safety and efficacy.
OPPORTUNITY:
Gene therapy holds immense potential for treating a wide range of genetic disorders and rare diseases.
Improved Manufacturing and Delivery is the main opportunity in this market.
Advances in manufacturing technologies and delivery methods are making gene therapies more accessible and cost-effective. Streamlining the production process and enhancing delivery efficiency can improve patient access to these treatments.
CHALLENGES:
Efficiently delivering the therapeutic genes to target cells in the body is a significant challenge in gene therapy.
A limited Understanding of Genetic Diseases is the biggest challenge in this market.
Despite significant progress, our understanding of many genetic diseases is still incomplete, which can hinder the identification of precise genetic targets and the development of effective therapies.
Ukraine and Russia account for around 2% of Merck's business, and neither nation has any production facilities. GlaxoSmithKline may also be impacted. The British pharmaceutical company has 28 Ukrainian sites out of 240 in its phase 3 research of otilimab in rheumatoid arthritis patients. GSK previously announced that it would discontinue the development of otilimab in 2021. According to the clinical research organisation Global Clinical Studies, Ukraine has over 2,560 public medical facilities with expertise in performing international studies, and there are roughly 520 active trials each year. The conflict's impact on clinical studies might be far-reaching. According to the FDA's clinical trials database, the biopharma sector is presently evaluating 255 medicines and devices in clinical studies with at least one Ukraine location. The gene therapy market is based on research and development they are increasing their prices up to 4-5% because of demand in the market.
IMPACT OF ONGOING RECESSION
One of the great attractions of treating patients by delivering DNA or RNA to their cells in the initial rush of public excitement about gene therapy 20 years ago was the promise that these agents might be made fast. It appeared to be a way to shave years off the development of therapeutics, remembers Nick Lemoine, a molecular oncologist and head of Queen Mary University of London's Barts Cancer Institute. Small-molecule medicines often take 15 years to gain approval. However, we got from proof of concept to clinical trial with the first gene therapy for breast cancer in five years. Despite dismal outcomes and declining financing in gene therapy, academic researchers persisted. They created safer and more effective delivery systems and put them through a continual stream of clinical studies involving a small number of patients. More than 2,300 gene-therapy trials, the majority of which were small-scale academic research, have been conducted to date across a wide range of illness targets and techniques. These studies have the potential to reorient the sector dramatically, and participants are learning to be realistic about safety. In an Ongoing recession, all this data from gene therapy increases their product and service price by up to 2-3%. The volume of research being conducted in the Russia-Ukraine region has pharmaceutical businesses rushing, just like they did during the height of the recession.
By Vector Type
Non-Viral Vector
Viral Vector
By Therapy
Ex Vivo Therapy
In Vivo Therapy
By Gene Type
Antigen
Growth factors
Tumor Suppressor
Cytokine
Suicide
Receptors
Deficiency
Others
By Application
Neurological Disorders
Rare Diseases
Oncological Disorders
Other Diseases
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSIS
North America: North America led the gene therapy market and generated the lion's share of total revenue. During the projection period, this area is likely to become the largest routine manufacturer of gene therapy in terms of approvals and revenue produced. Increased R&D spending from major and small firms in the creation of optimum therapeutic medications is expected to drive the market even more.
Asia Pacific: The Asia Pacific area is expected to be the fastest expanding. This is due to the country's enormous population, which has unmet medical requirements, as well as the growing demand for breakthrough technology in the treatment of uncommon but more widespread diseases. The Asia Pacific market for commercial use of genetic treatments is expected to rise significantly over the projected period, owing to the easy availability of resources, the local presence of key businesses, and rising government funding.
Some major key players in Gene Therapy Market are REGENXBIO, Inc., Taxus Cardium Pharmaceuticals Group, Inc., Oxford BioMedica plc, Bristol-Myers Squibb Company, Dimension Therapeutics, Inc., Applied Genetic Technologies Corporation, SANOFI, bluebird Bio, Inc., Novartis AG, F. Hoffmann-La Roche Ltd. and other players.
In 2021: Biogen Inc. reported favourable Phase 3 STAR trial findings for timrepigene emparvovec (BIIB111/AAV2-REP1), an experimental gene therapy for the treatment of choroideremia.
In 2021: Spark Therapeutics announced that the first study participant in the United States has been dosed as part of an international gene therapy clinical trial for Pompe Disease.
In 2020: Jazz Pharmaceuticals plc and its partner PharmaMar announced a favourable outcome for their ATLANTIS Phase 3 trial of Zepzelca in combination with Doxorubicin
| Report Attributes | Details |
| Market Size in 2022 | US$ 7.35 Bn |
| Market Size by 2030 | US$ 30.15 Bn |
| CAGR | CAGR of 19.3% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Vector Type (Non-Viral Vector, Viral Vector,) • By Therapy (Ex Vivo Therapy, In Vivo Therapy) • By Gene Type (Antigen, Growth factors, Tumor Suppressor, Cytokine, Suicide, Receptors, Deficiency, Others) • By Application (Neurological Disorders, Rare Diseases, Oncological Disorders, Other Diseases) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | REGENXBIO, Inc., Taxus Cardium Pharmaceuticals Group, Inc., Oxford BioMedica plc, Bristol-Myers Squibb Company, Dimension Therapeutics, Inc., Applied Genetic Technologies Corporation, SANOFI, bluebird Bio, Inc., Novartis AG, F. Hoffmann-La Roche Ltd. |
| Key Drivers | • Significant progress in gene editing tools such as CRISPR-Cas9 has revolutionized the field of gene therapy. • A positive regulatory environment is a significant driving force in this industry. |
| Market Restraints | • Gene therapy research and development involve complex scientific processes, rigorous clinical trials, and extensive regulatory requirements. • Manufacturing and Scale-up Challenges are the primary market restraints. |
Ans. The Compound Annual Growth rate for Gene Therapy Market over the forecast period is 19.3%.
Ans. USD 30.15 Billion is the projected Gene Therapy market size of the market by 2030.
Ans. The forthcoming trends in the Gene Therapy Market include increased funding for R&D activities related to gene therapy and increased awareness of gene therapy, which will drive worldwide market growth. Furthermore, increased government funding, ethical acceptance of gene therapy for cancer treatment, and an increase in cancer prevalence promote market expansion.
Ans. The largest geographical market for Gene Therapy is North America.
Ans. The Gene Therapy Market includes the following countries: the United States, Canada, Mexico, Germany, France, the United Kingdom, Italy, Russia, Spain, the Netherlands, Switzerland, Belgium, Turkey, the Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, and others.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Gene Therapy Market Segmentation, By Vector Type
8.1 Non-Viral Vector
8.2 Viral Vector
9. Gene Therapy Market Segmentation, By Therapy
9.1 Ex Vivo Therapy
9.2 In-Vivo Therapy
10. Gene Therapy Market Segmentation, By Gene Type
10.1 Antigen
10.2 Growth factors
10.3 Tumor Suppressor
10.4 Cytokine
10.5 Suicide
10.6 Receptors
10.7 Deficiency
10.8 Others
11. Gene Therapy Market Segmentation, By Application
11.1 Neurological Disorders
11.2 Rare Diseases
11.3 Oncological Disorders
11.4 Other Diseases
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Gene Therapy Market by Country
12.2.2 North America Gene Therapy Market by Vector Type
12.2.3 North America Gene Therapy Market by Therapy
12.2.4 North America Gene Therapy Market by Gene Type
12.2.5 North America Gene Therapy Market by Application
12.2.6 USA
12.2.6.1 USA Gene Therapy Market by Vector Type
12.2.6.2 USA Gene Therapy Market by Therapy
12.2.6.3 USA Gene Therapy Market by Gene Type
12.2.6.4 USA Gene Therapy Market by Application
12.2.7 Canada
12.2.7.1 Canada Gene Therapy Market by Vector Type
12.2.7.2 Canada Gene Therapy Market by Therapy
12.2.7.3 Canada Gene Therapy Market by Gene Type
12.2.7.4 Canada Gene Therapy Market by Application
12.2.8 Mexico
12.2.8.1 Mexico Gene Therapy Market by Vector Type
12.2.8.2 Mexico Gene Therapy Market by Therapy
12.2.8.3 Mexico Gene Therapy Market by Gene Type
12.2.8.4 Mexico Gene Therapy Market by Application
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Eastern Europe Gene Therapy Market by Country
12.3.1.2 Eastern Europe Gene Therapy Market by Vector Type
12.3.1.3 Eastern Europe Gene Therapy Market by Therapy
12.3.1.4 Eastern Europe Gene Therapy Market by Gene Type
12.3.1.5 Eastern Europe Gene Therapy Market by Application
12.3.1.6 Poland
12.3.1.6.1 Poland Gene Therapy Market by Vector Type
12.3.1.6.2 Poland Gene Therapy Market by Therapy
12.3.1.6.3 Poland Gene Therapy Market by Gene Type
12.3.1.6.4 Poland Gene Therapy Market by Application
12.3.1.7 Romania
12.3.1.7.1 Romania Gene Therapy Market by Vector Type
12.3.1.7.2 Romania Gene Therapy Market by Therapy
12.3.1.7.3 Romania Gene Therapy Market by Gene Type
12.3.1.7.4 Romania Gene Therapy Market by Application
12.3.1.8 Hungary
12.3.1.8.1 Hungary Gene Therapy Market by Vector Type
12.3.1.8.2 Hungary Gene Therapy Market by Therapy
12.3.1.8.3 Hungary Gene Therapy Market by Gene Type
12.3.1.8.4 Hungary Gene Therapy Market by Application
12.3.1.9 Turkey
12.3.1.9.1 Turkey Gene Therapy Market by Vector Type
12.3.1.9.2 Turkey Gene Therapy Market by Therapy
12.3.1.9.3 Turkey Gene Therapy Market by Gene Type
12.3.1.9.4 Turkey Gene Therapy Market by Application
12.3.1.10 Rest of Eastern Europe
12.3.1.10.1 Rest of Eastern Europe Gene Therapy Market by Vector Type
12.3.1.10.2 Rest of Eastern Europe Gene Therapy Market by Therapy
12.3.1.10.3 Rest of Eastern Europe Gene Therapy Market by Gene Type
12.3.1.10.4 Rest of Eastern Europe Gene Therapy Market by Application
12.3.2 Western Europe
12.3.2.1 Western Europe Gene Therapy Market by Country
12.3.2.2 Western Europe Gene Therapy Market by Vector Type
12.3.2.3 Western Europe Gene Therapy Market by Therapy
12.3.2.4 Western Europe Gene Therapy Market by Gene Type
12.3.2.5 Western Europe Gene Therapy Market by Application
12.3.2.6 Germany
12.3.2.6.1 Germany Gene Therapy Market by Vector Type
12.3.2.6.2 Germany Gene Therapy Market by Therapy
12.3.2.6.3 Germany Gene Therapy Market by Gene Type
12.3.2.6.4 Germany Gene Therapy Market by Application
12.3.2.7 France
12.3.2.7.1 France Gene Therapy Market by Vector Type
12.3.2.7.2 France Gene Therapy Market by Therapy
12.3.2.7.3 France Gene Therapy Market by Gene Type
12.3.2.7.4 France Gene Therapy Market by Application
12.3.2.8 UK
12.3.2.8.1 UK Gene Therapy Market by Vector Type
12.3.2.8.2 UK Gene Therapy Market by Therapy
12.3.2.8.3 UK Gene Therapy Market by Gene Type
12.3.2.8.4 UK Gene Therapy Market by Application
12.3.2.9 Italy
12.3.2.9.1 Italy Gene Therapy Market by Vector Type
12.3.2.9.2 Italy Gene Therapy Market by Therapy
12.3.2.9.3 Italy Gene Therapy Market by Gene Type
12.3.2.9.4 Italy Gene Therapy Market by Application
12.3.2.10 Spain
12.3.2.10.1 Spain Gene Therapy Market by Vector Type
12.3.2.10.2 Spain Gene Therapy Market by Therapy
12.3.2.10.3 Spain Gene Therapy Market by Gene Type
12.3.2.10.4 Spain Gene Therapy Market by Application
12.3.2.11 Netherlands
12.3.2.11.1 Netherlands Gene Therapy Market by Vector Type
12.3.2.11.2 Netherlands Gene Therapy Market by Therapy
12.3.2.11.3 Netherlands Gene Therapy Market by Gene Type
12.3.2.11.4 Netherlands Gene Therapy Market by Application
12.3.2.12 Switzerland
12.3.2.12.1 Switzerland Gene Therapy Market by Vector Type
12.3.2.12.2 Switzerland Gene Therapy Market by Therapy
12.3.2.12.3 Switzerland Gene Therapy Market by Gene Type
12.3.2.12.4 Switzerland Gene Therapy Market by Application
12.3.2.13 Austria
12.3.2.13.1 Austria Gene Therapy Market by Vector Type
12.3.2.13.2 Austria Gene Therapy Market by Therapy
12.3.2.13.3 Austria Gene Therapy Market by Gene Type
12.3.2.13.4 Austria Gene Therapy Market by Application
12.3.2.14 Rest of Western Europe
12.3.2.14.1 Rest of Western Europe Gene Therapy Market by Vector Type
12.3.2.14.2 Rest of Western Europe Gene Therapy Market by Therapy
12.3.2.14.3 Rest of Western Europe Gene Therapy Market by Gene Type
12.3.2.14.4 Rest of Western Europe Gene Therapy Market by Application
12.4 Asia-Pacific
12.4.1 Asia Pacific Gene Therapy Market by Country
12.4.2 Asia Pacific Gene Therapy Market by Vector Type
12.4.3 Asia Pacific Gene Therapy Market by Therapy
12.4.4 Asia Pacific Gene Therapy Market by Gene Type
12.4.5 Asia Pacific Gene Therapy Market by Application
12.4.6 China
12.4.6.1 China Gene Therapy Market by Vector Type
12.4.6.2 China Gene Therapy Market by Therapy
12.4.6.3 China Gene Therapy Market by Gene Type
12.4.6.4 China Gene Therapy Market by Application
12.4.7 India
12.4.7.1 India Gene Therapy Market by Vector Type
12.4.7.2 India Gene Therapy Market by Therapy
12.4.7.3 India Gene Therapy Market by Gene Type
12.4.7.4 India Gene Therapy Market by Application
12.4.8 Japan
12.4.8.1 Japan Gene Therapy Market by Vector Type
12.4.8.2 Japan Gene Therapy Market by Therapy
12.4.8.3 Japan Gene Therapy Market by Gene Type
12.4.8.4 Japan Gene Therapy Market by Application
12.4.9 South Korea
12.4.9.1 South Korea Gene Therapy Market by Vector Type
12.4.9.2 South Korea Gene Therapy Market by Therapy
12.4.9.3 South Korea Gene Therapy Market by Gene Type
12.4.9.4 South Korea Gene Therapy Market by Application
12.4.10 Vietnam
12.4.10.1 Vietnam Gene Therapy Market by Vector Type
12.4.10.2 Vietnam Gene Therapy Market by Therapy
12.4.10.3 Vietnam Gene Therapy Market by Gene Type
12.4.10.4 Vietnam Gene Therapy Market by Application
12.4.11 Singapore
12.4.11.1 Singapore Gene Therapy Market by Vector Type
12.4.11.2 Singapore Gene Therapy Market by Therapy
12.4.11.3 Singapore Gene Therapy Market by Gene Type
12.4.11.4 Singapore Gene Therapy Market by Application
12.4.12 Australia
12.4.12.1 Australia Gene Therapy Market by Vector Type
12.4.12.2 Australia Gene Therapy Market by Therapy
12.4.12.3 Australia Gene Therapy Market by Gene Type
12.4.12.4 Australia Gene Therapy Market by Application
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Gene Therapy Market by Vector Type
12.4.13.2 Rest of Asia-Pacific Gene Therapy Market by Therapy
12.4.13.3 Rest of Asia-Pacific Gene Therapy Market by Gene Type
12.4.13.4 Rest of Asia-Pacific Gene Therapy Market by Application
12.5 Middle East & Africa
12.5.1 Middle East
12.5.1.1 Middle East Gene Therapy Market by Country
12.5.1.2 Middle East Gene Therapy Market by Vector Type
12.5.1.3 Middle East Gene Therapy Market by Therapy
12.5.1.4 Middle East Gene Therapy Market by Gene Type
12.5.1.5 Middle East Gene Therapy Market by Application
12.5.1.6 UAE
12.5.1.6.1 UAE Gene Therapy Market by Vector Type
12.5.1.6.2 UAE Gene Therapy Market by Therapy
12.5.1.6.3 UAE Gene Therapy Market by Gene Type
12.5.1.6.4 UAE Gene Therapy Market by Application
12.5.1.7 Egypt
12.5.1.7.1 Egypt Gene Therapy Market by Vector Type
12.5.1.7.2 Egypt Gene Therapy Market by Therapy
12.5.1.7.3 Egypt Gene Therapy Market by Gene Type
12.5.1.7.4 Egypt Gene Therapy Market by Application
12.5.1.8 Saudi Arabia
12.5.1.8.1 Saudi Arabia Gene Therapy Market by Vector Type
12.5.1.8.2 Saudi Arabia Gene Therapy Market by Therapy
12.5.1.8.3 Saudi Arabia Gene Therapy Market by Gene Type
12.5.1.8.4 Saudi Arabia Gene Therapy Market by Application
12.5.1.9 Qatar
12.5.1.9.1 Qatar Gene Therapy Market by Vector Type
12.5.1.9.2 Qatar Gene Therapy Market by Therapy
12.5.1.9.3 Qatar Gene Therapy Market by Gene Type
12.5.1.9.4 Qatar Gene Therapy Market by Application
12.5.1.10 Rest of Middle East
12.5.1.10.1 Rest of Middle East Gene Therapy Market by Vector Type
12.5.1.10.2 Rest of Middle East Gene Therapy Market by Therapy
12.5.1.10.3 Rest of Middle East Gene Therapy Market by Gene Type
12.5.1.10.4 Rest of Middle East Gene Therapy Market by Application
12.5.2. Africa
12.5.2.1 Africa Gene Therapy Market by Country
12.5.2.2 Africa Gene Therapy Market by Vector Type
12.5.2.3 Africa Gene Therapy Market by Therapy
12.5.2.4 Africa Gene Therapy Market by Gene Type
12.5.2.5 Africa Gene Therapy Market by Application
12.5.2.6 Nigeria
12.5.2.6.1 Nigeria Gene Therapy Market by Vector Type
12.5.2.6.2 Nigeria Gene Therapy Market by Therapy
12.5.2.6.3 Nigeria Gene Therapy Market by Gene Type
12.5.2.6.4 Nigeria Gene Therapy Market by Application
12.5.2.7 South Africa
12.5.2.7.1 South Africa Gene Therapy Market by Vector Type
12.5.2.7.2 South Africa Gene Therapy Market by Therapy
12.5.2.7.3 South Africa Gene Therapy Market by Gene Type
12.5.2.7.4 South Africa Gene Therapy Market by Application
12.5.2.8 Rest of Africa
12.5.2.8.1 Rest of Africa Gene Therapy Market by Vector Type
12.5.2.8.2 Rest of Africa Gene Therapy Market by Therapy
12.5.2.8.3 Rest of Africa Gene Therapy Market by Gene Type
12.5.2.8.4 Rest of Africa Gene Therapy Market by Application
12.6. Latin America
12.6.1 Latin America Gene Therapy Market by Country
12.6.2 Latin America Gene Therapy Market by Vector Type
12.6.3 Latin America Gene Therapy Market by Therapy
12.6.4 Latin America Gene Therapy Market by Gene Type
12.6.5 Latin America Gene Therapy Market by Application
12.6.6 Brazil
12.6.6.1 Brazil Gene Therapy Market by Vector Type
12.6.6.2 Brazil Africa Gene Therapy Market by Therapy
12.6.6.3 Brazil Gene Therapy Market by Gene Type
12.6.6.4 Brazil Gene Therapy Market by Application
12.6.7 Argentina
12.6.7.1 Argentina Gene Therapy Market by Vector Type
12.6.7.2 Argentina Gene Therapy Market by Therapy
12.6.7.3 Argentina Gene Therapy Market by Gene Type
12.6.7.4 Argentina Gene Therapy Market by Application
12.6.8 Colombia
12.6.8.1 Colombia Gene Therapy Market by Vector Type
12.6.8.2 Colombia Gene Therapy Market by Therapy
12.6.8.3 Colombia Gene Therapy Market by Gene Type
12.6.8.4 Colombia Gene Therapy Market by Application
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Gene Therapy Market by Vector Type
12.6.9.2 Rest of Latin America Gene Therapy Market by Therapy
12.6.9.3 Rest of Latin America Gene Therapy Market by Gene Type
12.6.9.4 Rest of Latin America Gene Therapy Market by Application
13 Company Profile
13.1 REGENXBIO, Inc.
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Treatment/Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Taxus Cardium Pharmaceuticals Group, Inc
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Treatment/Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Oxford BioMedica plc
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Treatment/Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Bristol-Myers Squibb Company
13.4 Company Overview
13.4.2 Financials
13.4.3 Treatment/Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Dimension Therapeutics, Inc.
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Treatment/Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Applied Genetic Technologies Corporation
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Treatment/Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 SANOFI
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Treatment/Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 bluebird Bio, Inc.
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Treatment/Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Novartis AG
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Product/Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 F. Hoffmann-La Roche Ltd.
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Product/Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. USE Cases and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Serum-free Media Market size was estimated USD 1.5 billion in 2022 and is expected to reach USD 4.0 billion by 2030 at a CAGR of 13.1% during the forecast period of 2023-2030.
The Cell Freezing Media Market size was estimated USD 141.3 million in 2022 and is expected to reach USD 296.3 million by 2030 at a CAGR of 9.7% during the forecast period of 2023-2030.
The Antimicrobial Susceptibility Testing Market Size was valued at USD 3.57 billion in 2023 and is expected to reach USD 5.35 billion by 2031 and grow at a CAGR of 5.2% over the forecast period 2024-2031.
The Live Cell Encapsulation Market size was estimated USD 211.7 million in 2022 and is expected to reach USD 289.7 million by 2030 at a CAGR of 4.0% during the forecast period of 2023-2030.
The Protein A Resin Market, size was estimated USD 1.4 billion in 2022 and is expected to reach USD 2.97 billion by 2030 at a CAGR of 9.9% during the forecast period of 2023-2030.
The Medical Decision Support Systems for Sepsis Market Size was valued at USD 36.17 million in 2022, and is expected to reach USD 211.51 million by 2030, and grow at a CAGR of 24.7% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
